Ungerleider RS - Search Results

1

Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.

Smith MA, Rubinstein L, Ungerleider RS. Smith MA, et al. Among authors: ungerleider rs. Med Pediatr Oncol. 1994;23(2):86-98. doi: 10.1002/mpo.2950230205. Med Pediatr Oncol. 1994. PMID: 8202047 Review.

2

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Smith M, et al. J Clin Oncol. 1996 Jan;14(1):18-24. doi: 10.1200/JCO.1996.14.1.18. J Clin Oncol. 1996. PMID: 8558195

3

Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.

Smith MA, Rubinstein L, Cazenave L, Ungerleider RS, Maurer HM, Heyn R, Khan FM, Gehan E. Smith MA, et al. Among authors: ungerleider rs. J Natl Cancer Inst. 1993 Apr 7;85(7):554-8. doi: 10.1093/jnci/85.7.554. J Natl Cancer Inst. 1993. PMID: 8455202

4

Conduct of phase I trials in children with cancer.

Smith M, Bernstein M, Bleyer WA, Borsi JD, Ho P, Lewis IJ, Pearson A, Pein F, Pratt C, Reaman G, Riccardi R, Seibel N, Trueworthy R, Ungerleider R, Vassal G, Vietti T. Smith M, et al. J Clin Oncol. 1998 Mar;16(3):966-78. doi: 10.1200/JCO.1998.16.3.966. J Clin Oncol. 1998. PMID: 9508179

5

Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma.

Smith MA, Ungerleider RS, Horowitz ME, Simon R. Smith MA, et al. Among authors: ungerleider rs. J Natl Cancer Inst. 1991 Oct 16;83(20):1460-70. doi: 10.1093/jnci/83.20.1460. J Natl Cancer Inst. 1991. PMID: 1833556

6

Neoadjuvant therapy in cancer treatment.

Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, Carter CL, Friedman MA. Trimble EL, et al. Among authors: ungerleider rs. Cancer. 1993 Dec 1;72(11 Suppl):3515-24. doi: 10.1002/1097-0142(19931201)72:11+<3515::aid-cncr2820721619>3.0.co;2-a. Cancer. 1993. PMID: 8242583 Review.

7

Children and cancer. A perspective from the Cancer Therapy Evaluation Program, National Cancer Institute.

Smith M, Simon R, Cain D, Ungerleider RS. Smith M, et al. Among authors: ungerleider rs. Cancer. 1993 May 15;71(10 Suppl):3422-8. doi: 10.1002/1097-0142(19930515)71:10+<3422::aid-cncr2820711748>3.0.co;2-4. Cancer. 1993. PMID: 8490893

8

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.

Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Smith MA, et al. Among authors: ungerleider rs. J Clin Oncol. 1997 Jul;15(7):2736-43. doi: 10.1200/JCO.1997.15.7.2736. J Clin Oncol. 1997. PMID: 9215848

9

Equal participation of minority patients in U.S. national pediatric cancer clinical trials.

Bleyer WA, Tejeda HA, Murphy SB, Brawley OW, Smith MA, Ungerleider RS. Bleyer WA, et al. Among authors: ungerleider rs. J Pediatr Hematol Oncol. 1997 Sep-Oct;19(5):423-7. doi: 10.1097/00043426-199709000-00003. J Pediatr Hematol Oncol. 1997. PMID: 9329463

10

National cancer clinical trials: children have equal access; adolescents do not.

Bleyer WA, Tejeda H, Murphy SB, Robison LL, Ross JA, Pollock BH, Severson RK, Brawley OW, Smith MA, Ungerleider RS. Bleyer WA, et al. Among authors: ungerleider rs. J Adolesc Health. 1997 Dec;21(6):366-73. doi: 10.1016/S1054-139X(97)00110-9. J Adolesc Health. 1997. PMID: 9401854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page